Is My Nanotechnology Safe? Approaches For NanoEHS Risk Assessments
This webinar will discuss how to use tiered approaches to evaluate the benefits and risks of novel nanomaterials and product formulations containing nanomaterials, as well as common risk mitigation approaches.
- Event Type:
- Mar. 10, 2020
- 10:00 AM PDT | 01:00 PM EDT
The FDA is still treating nanomaterials on a case by case basis. How can you determine if the nanotechnology you are considering is safe? FDA applications require proof of safety, as does public perception in an environment where using nanomaterials to improve products still creates fear around unknown aspects of nanotechnology. Responsible commercialization and stewardship require evaluating the potential risks. Yet peer-reviewed literature often appears to have conflicting results as headlines. How can you make scientific sense of this?
This webinar will highlight important fundamental knowledge to enter the nanomaterial risk assessment space, and help you become familiar with measurements of nanomaterials needed to understand what key factors impact or reduce safety risks.
This webinar will enable you to use tiered approaches when performing nanomaterial and product risk assessments; perform better interpretation of NanoEHS literature and identify common mistakes in the literature; and identify risk mitigation approaches for nano enabled products.
- How are nanomaterials defined?
- FDA treatment of nanomaterials on a case by case basis
- Measuring nanomaterials
- Approaches for validating lower cost nano measurements
- Tiered approaches to NanoEHS risk assessment
- Avoiding misinterpretations in NanoEHS literature
- Risk mitigation approaches
- Life cycle analysis thinking
- Case study example
- Product Development Managers
- Manufacturing Managers
- Operations Directors
- R&D Directors
- Safety or EH&S Officers
- Risk Management Officers
- Staff Scientists
- Formulation Scientists
- Analytical Chemists
From industries such as Consumer Goods, Medical Devices, Dental Products and Devices, Pharmaceutical Formulation, Cosmetics and more.
Rob MacCuspie holds a Ph.D. in Nanotechnology and Materials Chemistry, and has twenty years of experience in nanotechnology research, NanoEHS, and responsible commercialization of nano-enabled products. Over his career, he has worked in the National Lab system at the National Institute of Standards and Technology, the Air Force Research Laboratory, and US FDA, as well as being first faculty at Florida Polytechnic University and Director of Nanotechnology and Multifunctional Materials Programs. He holds 1 US patent, has written 42 publications cited over 2,800 times for an h-index of 28.